CD83 Is a New Potential Biomarker and Therapeutic Target for Hodgkin Lymphoma

Haematologica - Italy
doi 10.3324/haematol.2017.178384
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Ferrata Storti Foundation (Haematologica)

Related search

MiR-30a: A Novel Biomarker and Potential Therapeutic Target for Cancer

Journal of Oncology
Oncology
2018English

Transgelin in Bladder Cancer: A Potential Biomarker and Therapeutic Target

EBioMedicine
BiochemistryMedicineGeneticsMolecular Biology
2019English

C-Met as a Potential Therapeutic Target and Biomarker in Cancer

Therapeutic Advances in Medical Oncology
Oncology
2011English

DDX49 Is a Novel Biomarker and Therapeutic Target for Lung Cancer Metastases

Journal of Cellular and Molecular Medicine
Molecular MedicineCell Biology
2020English

SLAMF7 (CD319/CS1) Is Expressed in Plasmablastic Lymphoma and Is a Potential Diagnostic Marker and Therapeutic Target

British Journal of Haematology
Hematology
2018English

ROR2 Is a Novel Prognostic Biomarker and a Potential Therapeutic Target in Leiomyosarcoma and Gastrointestinal Stromal Tumour

Journal of Pathology
Forensic MedicinePathology
2012English

Circulating Dendritic Cells Deficiencies as a New Biomarker in Classical Hodgkin Lymphoma

British Journal of Haematology
Hematology
2018English

Aminoacylase 3 Is a New Potential Marker and Therapeutic Target in Hepatocellular Carcinoma

Journal of Cancer
Oncology
2018English

CD83: Activation Marker for Antigen Presenting Cells and Its Therapeutic Potential

Frontiers in Immunology
AllergyImmunology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy